Trial Profile
A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Caspofungin (Primary)
- Indications Aspergillosis; Candidiasis; Invasive bronchopulmonary aspergillosis; Invasive candidiasis
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 10 May 2014 New trial record